Lomax Ward

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets. To date, Phenomic has raised over $15 million and has built a world-class team of employees, advisors, and investors.

LGNs edge AI management software puts you in complete technical and financial control of your edge AI. This allows you to scale out edge AI products without exploding your costs.

We protect brands and defend democracy from harmful social media manipulation campaigns, also known as astroturfing.

Wayra is Telefónicas Corporate Venture Capital and Open Innovation platform. We invest in startups with the potential to offer innovative solutions to Telefónica and third parties, to support taking their Open Innovation initiatives to the next level. With a global presence, we have seven hubs in Europe (Spain -Madrid and Barcelona-, United Kingdom and Germany) and Latin America (Brazil, Argentina and Colombia), and teams operating in nine countries. Through our funds, we are also present in Silicon Valley and Israel. Since launching 15 years ago, Wayra has invested €233M in +1,100 startups and currently has +530 startups in the portfolio, of which +190 work with Telefónica. We also have a network of more than 140 partners and customers, and two innovation platforms (Alaian and Open Future) open to third parties.

SURFnCODE is a builder of products and companies. We partner with hand-picked founders of early-stage companies whose missions we believe in to create new products and scale teams into standalone businesses. We are hands-on co-founders that care about the details. Our goal is to build great long-lasting businesses that improve lives and make life richer and more enjoyable. Our values create a culture of shared success across our companies, driving learning and collaboration. Were actively hiring - check this out: careers.surfncode.io

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets. To date, Phenomic has raised over $15 million and has built a world-class team of employees, advisors, and investors.

LGNs edge AI management software puts you in complete technical and financial control of your edge AI. This allows you to scale out edge AI products without exploding your costs.

Since 2019 our mission has been to make it easier for LPs from around the world to find the right European ventures funds to invest into and for GPs the right investors, by building a global community of forward thinking collaborators. DC also runs ALLOCATE.GP which is Europes original and best VC pitch event & community for tech venture capital GPs and the LPs who invest into them. Events are run not-for-profit. 🐲 Here be dragons.

We protect brands and defend democracy from harmful social media manipulation campaigns, also known as astroturfing.

Wayra is Telefónicas Corporate Venture Capital and Open Innovation platform. We invest in startups with the potential to offer innovative solutions to Telefónica and third parties, to support taking their Open Innovation initiatives to the next level. With a global presence, we have seven hubs in Europe (Spain -Madrid and Barcelona-, United Kingdom and Germany) and Latin America (Brazil, Argentina and Colombia), and teams operating in nine countries. Through our funds, we are also present in Silicon Valley and Israel. Since launching 15 years ago, Wayra has invested €233M in +1,100 startups and currently has +530 startups in the portfolio, of which +190 work with Telefónica. We also have a network of more than 140 partners and customers, and two innovation platforms (Alaian and Open Future) open to third parties.